Article

A Human T-Cell Leukemia Virus Type 1 Regulatory Element Enhances the Immunogenicity of Human Immunodeficiency Virus Type 1 DNA Vaccines in Mice and Nonhuman Primates

Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA.
Journal of Virology (Impact Factor: 4.65). 08/2005; 79(14):8828-34. DOI: 10.1128/JVI.79.14.8828-8834.2005
Source: PubMed

ABSTRACT Plasmid DNA vaccines elicit potent and protective immune responses in numerous small-animal models of infectious diseases. However, their immunogenicity in primates appears less potent. Here we investigate a novel approach that optimizes regulatory elements in the plasmid backbone to improve the immunogenicity of DNA vaccines. Among various regions analyzed, we found that the addition of a regulatory sequence from the R region of the long terminal repeat from human T-cell leukemia virus type 1 (HTLV-1) to the cytomegalovirus (CMV) enhancer/promoter increased transgene expression 5- to 10-fold and improved cellular immune responses to human immunodeficiency virus type 1 (HIV-1) antigens. In cynomolgus monkeys, DNA vaccines containing the CMV enhancer/promoter with the HTLV-1 R region (CMV/R) induced markedly higher cellular immune responses to HIV-1 Env from clades A, B, and C and to HIV-1 Gag-Pol-Nef compared with the parental DNA vaccines. These data demonstrate that optimization of specific regulatory elements can substantially improve the immunogenicity of DNA vaccines encoding multiple antigens in small animals and in nonhuman primates. This strategy could therefore be explored as a potential method to enhance DNA vaccine immunogenicity in humans.

Download full-text

Full-text

Available from: Birgit Korioth-Schmitz, Jul 05, 2015
0 Followers
 · 
102 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The vaccinia virus (VACV) entry-fusion complex (EFC) is composed of at least nine membrane proteins. Immunization of mice with individual EFC genes induced corresponding protein-binding antibody but failed to protect against VACV intranasal challenge and only DNA encoding A28 elicited low neutralizing antibody. Because the A28 and H2 proteins interact, we determined the effect of immunizing with both genes simultaneously. This procedure greatly enhanced the amount of antibody that bound intact virions, neutralized infectivity, and provided partial protection against respiratory challenge. Neither injection of A28 and H2 plasmids at different sites or mixing A28 and H2 sera enhanced neutralizing antibody. The neutralizing antibody could be completely removed by binding to the A28 protein alone and the epitope was located in the C-terminal segment. These data suggest that the interaction of H2 with A28 stabilizes the immunogenic form of A28, mimicking an exposed region of the entry-fusion complex on infectious virions.
    Virology 09/2010; 405(1):41-9. DOI:10.1016/j.virol.2010.05.025
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: HSV-1 amplicon vectors elicit strong T-cell responses to encoded antigens but the qualitative nature of these responses is poorly understood. Antigen-specific CD4(+) and CD8(+) T-cell responses to amplicon and adenovirus (rAd5) vectors encoding HIV-1 gp120 were assessed following immunization of mice, by performing intracellular cytokine staining for IFNgamma, IL2 and TNFalpha, following stimulation of splenocytes with a HIV-1 Env peptide pool. The quality of the primary T-cell response to amplicon and rAd5 vectors was strikingly similar, but there were qualitative differences in responses to amplicon vectors that incorporated different promoters upstream of gp120 - suggesting that promoters can significantly influence immune response quality. When prime-boost combinations were studied, a rAd5 prime and amplicon boost elicited the highest T-cell response. Furthermore, protocols that incorporated a rAd5 prime consistently elicited a greater proportion of polyfunctional CD4(+) T-cells-regardless of boost. This suggests that initial priming can shape immune response quality after a boost. Overall, these findings provide insight into effective vector combinations for HIV-1 vaccine development.
    Vaccine 11/2007; 25(42):7410-21. DOI:10.1016/j.vaccine.2007.08.015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Thesis (Ph.D.)--University of Rochester. School of Medicine and Dentistry. Dept. of Microbiology and Immunology, 2007. Helper-free herpes simplex virus type-1 (HSV-1) amplicon vectors are replicationdefective, “gutless” plasmid-based gene transfer vectors that possess compelling advantages as potential vaccine delivery platforms. These advantages include: a favorable safety profile due to the lack of expression of virally-encoded immunomodulatory genes, the capacity to encode large amounts of foreign DNA and a broad host cell tropism - including the ability to directly transduce antigen presenting cells such as dendritic cells. Previous work from our laboratory has shown that a single injection of a helper-free HSV-1 amplicon vector can elicit potent and durable immune responses to an encoded HIV antigen, even in the face of preexisting immunity to HSV. The focus of this thesis was a three-pronged examination of the hypothesis that it might be possible to maximize HSV-1 amplicon vector-induced immune responses to encoded HIV-1 antigens by further optimizing antigen design and vector delivery strategies. As an initial focus, amplicons encoding a modified HIV-1 clade C Env antigen were generated and tested, in vivo, to determine whether addition of an immunodominant CTL tag had any effect on the antigen-specific CD8+ T cell response. This study showed that immunization of mice with an amplicon vector encoding the tagged envelope protein elicited potent and detectable cellular immune responses. Planned follow-up experiments on the immune response to amplicon vectors encoding multiple Env antigens were abandoned when other investigators published similar studies. The second focus of the thesis was a determination of whether the volume of buffer (and the associated route of delivery)in which a fixed dose of amplicon encoding a model HIV-1 antigen (gp120) is delivered might affect the CD8+T-cell immune response to amplicon encoded antigens. The underlying rationale was that a larger inoculum volume might result in higher levels of non-specific immune activation due to minor tissue damage, and more broad dissemination of the vector. This study revealed that the inoculum volume had a minimal effect on the measured immune response to either recombinant adenovirus serotype 5 (rAd5) or HSV-1 amplicon vectors encoding a model HIV-1 antigen. The third focus of this thesis was a multilayered examination of the magnitude and quality of CD4+ and CD8+ T-cell immune responses elicited by a heterologous prime boost regimen combining HSV-1 amplicon and rAd5 vectors that encoded the same HIV-1 antigen (gp120). A careful comparison of the magnitude and quality of the T cell response that was elicited, at acute and late time points, following immunization with HSV-1 amplicon and rAd5 vectors showed that HSV-1 amplicon vectors and rAd5 vectors that encoded gp120 from the same transcriptional regulatory element elicited primary T cell responses that were similar both in magnitude and quality. In contrast, HSV-1 amplicon vectors that incorporated different promoter elements upstream of gp120 elicited qualitatively and quantitatively distinct antigenspecific T cell response profiles. Further, the heterologous combination of a rAd5 vector prime and a HSV-1 amplicon vector boost was found to yield the best combination of cellular immune response magnitude and quality. Taken together, these findings point the way forward to novel and more effective use of the HSV-1 amplicon vector system for HIV-1 vaccine development.